BiaCure Therapies Inc.

medical devices

About

Onychomycosis is a pervasive, disfiguring, and often painful infection of the nail, surface of the nail bed, and/or nail matrix caused by fungi that are ubiquitous in the environment Over 35 million patients in the US suffer from this type of infection, including approximately 1 in 3 diabetic patients. Research demonstrates an increased risk of other foot disorders and amputations in diabetic patients with onychomycosis. There are no current treatments that effectively treat this type of infection. Our patented TherawaveTM 100 technology delivers a safe and effective High Frequency Energy (HFE) precisely to the infected nail plate and surface nail bed to eliminate the fungal infection while sparing surrounding tissue. *The Therawave100 is under development and is not available for sale.

Technologies

Outlook GoDaddy Hosting Google Font API Bootstrap Framework Mobile Friendly WordPress.org reCAPTCHA Apache

Keywords

medical device dermatology podiatry toe fungus medical equipment manufacturing medical innovation treatment technology medical r&d ultrasound-based customization non-invasive therapy patient-specific medical devices clinical solutions non-invasive nail therapy device innovation medical devices medical equipment and supplies manufacturing high frequency energy patented biapulse technology medical device for onychomycosis multi-toe treatment device clinical development nail disorder treatment ai algorithms for nail treatment healthcare technology fungal nail infection innovative fungal treatment medical device prototyping regulatory compliance b2b high-frequency energy

Location

Milwaukee, Wisconsin, United States

Related Companies

Companies in the same industry